| Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms (NCT05455294) | Jacqueline Garcia, MD | 2022-07-18 |
| Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002) (NCT05233618) | Karen Ballen, MD | 2022-07-13 |
| A New Prognostic Stratification-based Safety and Efficacy Study of Ruxolitinib in Myelofibrosis (NCT05447260) | Qilu Hospital of Shandong University | 2022-06-10 |
| Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib (NCT05280509) | Telios Pharma, Inc. | 2022-06-09 |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia (NCT05320198) | Disc Medicine, Inc | 2022-06-06 |
| Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. (NCT04771572) | Newave Pharmaceutical Inc | 2022-05-08 |
| Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera (NCT06516406) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2022-05-06 |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis (NCT05371964) | Geron Corporation | 2022-05-04 |
| A Study to Evaluate the Demographics and Treatment Patterns of Myelofibrosis Patients Treated With Ruxolitinib in Turkey (NCT07357441) | Novartis Pharmaceuticals | 2022-04-07 |
| An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms (NCT05123365) | University of California, Irvine | 2022-01-03 |
| A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis (NCT05037760) | Takeda | 2021-12-16 |
| Two Step Haplo With Radiation Conditioning (NCT05031897) | Thomas Jefferson University | 2021-10-25 |
| Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. (NCT04866056) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-09-30 |
| A Study to Assess Real-World Patient-Reported Outcomes With Fedratinib for Myelofibrosis Post-Ruxolitinib (NCT05665192) | Bristol-Myers Squibb | 2021-08-02 |
| Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment. (NCT04851535) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-07-28 |
| To Evaluate the Effect of Food on the Pharmacokinetics of TQ05105 Tablets in Healthy Adult Subjects (NCT05982106) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-07-19 |
| To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213) (NCT04629508) | Incyte Corporation | 2021-07-12 |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study (NCT05972577) | Ohio State University Comprehensive Cancer Center | 2021-06-11 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis (NCT04679870) | Galecto Biotech AB | 2021-06-09 |
| Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation (NCT03602898) | Fred Hutchinson Cancer Center | 2021-06-01 |
| To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) (NCT04551053) | Incyte Corporation | 2021-05-26 |
| To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) (NCT04551066) | Incyte Corporation | 2021-05-24 |
| Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia (NCT04543279) | Washington University School of Medicine | 2021-05-03 |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment (NCT04576156) | Geron Corporation | 2021-04-12 |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (NCT04603495) | Novartis Pharmaceuticals | 2021-04-09 |
| A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) (NCT04817007) | Bristol-Myers Squibb | 2021-03-22 |
| A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis (NCT04562870) | Karyopharm Therapeutics Inc | 2021-03-17 |
| Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis (NCT04562389) | Karyopharm Therapeutics Inc | 2021-03-11 |
| A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (NCT04640025) | Incyte Corporation | 2021-03-10 |
| An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (NCT04717414) | Celgene | 2021-02-25 |
| Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (NCT04279847) | Incyte Corporation | 2021-02-23 |
| Methods of T Cell Depletion Trial (MoTD) (NCT04888741) | University of Birmingham | 2021-02-22 |
| Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT (NCT04629430) | University of Virginia | 2021-02-19 |
| Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (NCT04676529) | Syntara | 2021-02-18 |
| Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis (NCT04617028) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2021-02-05 |
| An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib (NCT04485260) | Kartos Therapeutics, Inc. | 2021-01-28 |
| A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy (NCT04354727) | Ascentage Pharma Group Inc. | 2020-12-15 |
| Study of Select Combinations in Adults With Myelofibrosis (NCT04283526) | Novartis Pharmaceuticals | 2020-11-30 |
| KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF (NCT04640532) | Kartos Therapeutics, Inc. | 2020-11-17 |
| Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis (NCT04655118) | Telios Pharma, Inc. | 2020-10-22 |
| SARS-CoV-2 Donor-Recipient Immunity Transfer (NCT04666025) | City of Hope Medical Center | 2020-09-23 |
| Actuate 1901: 9-ING-41 in Myelofibrosis (NCT04218071) | Actuate Therapeutics Inc. | 2020-08-20 |
| Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis (NCT04217356) | University Health Network, Toronto | 2020-08-05 |
| HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation (NCT04464889) | Medigene AG | 2020-07-02 |
| Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant (NCT03964506) | Omar Aljitawi | 2020-07-01 |
| A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers (NCT04328844) | iOnctura | 2020-02-25 |
| A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis (NCT04176198) | Sumitomo Pharma America, Inc. | 2019-12-16 |
| Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation (NCT04060277) | City of Hope Medical Center | 2019-11-27 |
| European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study (NCT04153305) | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | 2019-10-08 |
| Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (NCT04097821) | Novartis Pharmaceuticals | 2019-09-26 |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (NCT03952039) | Celgene | 2019-09-09 |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (NCT03755518) | Celgene | 2019-03-27 |
| Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms (NCT03878199) | Ohio State University Comprehensive Cancer Center | 2019-02-20 |
| Hu8F4 in Treating Patients With Advanced Hematologic Malignancies (NCT02530034) | M.D. Anderson Cancer Center | 2019-01-31 |
| Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis. (NCT03886415) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2019-01-08 |
| Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant (NCT03438344) | City of Hope Medical Center | 2018-12-01 |
| The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase (NCT03907436) | University of California, Irvine | 2018-10-01 |
| Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (NCT03289910) | National Cancer Institute (NCI) | 2018-09-24 |
| Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. (NCT03427866) | Massachusetts General Hospital | 2018-08-28 |
| CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant (NCT03560752) | City of Hope Medical Center | 2018-08-20 |
| Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) (NCT03645824) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2018-06-04 |
| Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis (NCT03373877) | Samus Therapeutics, Inc. | 2018-05-24 |
| Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) (NCT03745378) | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | 2018-05-15 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (NCT03314974) | Masonic Cancer Center, University of Minnesota | 2018-03-30 |
| Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression (NCT03480360) | Dartmouth-Hitchcock Medical Center | 2018-03-28 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer (NCT03333486) | Roswell Park Cancer Institute | 2017-12-07 |
| Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia (NCT02730884) | M.D. Anderson Cancer Center | 2017-08-16 |
| Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) (NCT03136185) | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | 2017-07-18 |
| Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) (NCT02564536) | Washington University School of Medicine | 2017-06-01 |
| Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy (NCT03959371) | Margherita Maffioli | 2017-04-11 |
| A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis (NCT03069326) | Memorial Sloan Kettering Cancer Center | 2017-02-27 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NCT01962636) | Masonic Cancer Center, University of Minnesota | 2016-12-01 |
| Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis (NCT02934477) | Center for International Blood and Marrow Transplant Research | 2016-11-01 |
| Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis (NCT02784496) | M.D. Anderson Cancer Center | 2016-09-29 |
| Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG (NCT02916979) | Dartmouth-Hitchcock Medical Center | 2016-09-06 |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients (NCT02877082) | Emory University | 2016-09-01 |
| Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis (NCT02805868) | Northwestern University | 2016-06-01 |
| Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders (NCT02663648) | Shandong University | 2016-06-01 |
| Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg (NCT02742324) | French Innovative Leukemia Organisation | 2016-03-01 |
| Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) (NCT02268253) | Stemline Therapeutics, Inc. | 2016-02-10 |
| Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT (NCT02728700) | Stanford University | 2016-02-01 |
| Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (NCT02506933) | City of Hope Medical Center | 2015-12-21 |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies (NCT02556931) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-12-01 |
| Reduced Intensity Conditioning Transplant Using Haploidentical Donors (NCT02581007) | Northside Hospital, Inc. | 2015-10-26 |
| Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia (NCT02530619) | Northwestern University | 2015-10-09 |
| URMC Related Haplo-identical Donor BMT (NCT02660281) | University of Rochester | 2015-10-01 |
| Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor (NCT02426086) | Geron Corporation | 2015-08-28 |
| TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea (NCT02493530) | Vanderbilt-Ingram Cancer Center | 2015-07-01 |
| iCare for Cancer Patients (NCT02435550) | University of Florida | 2015-06-26 |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease (NCT02436135) | Gilead Sciences | 2015-06-05 |
| Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis (NCT02370706) | Novartis Pharmaceuticals | 2015-05-21 |
| Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCT02396134) | City of Hope Medical Center | 2015-05-21 |
| Ruxolitinib in Combination With Autotransplant (NCT02469974) | Marina Kremyanskaya | 2015-05-01 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors (NCT02440685) | Asana BioSciences | 2015-05-01 |
| Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source (NCT02167958) | Rafic Farah, MD | 2015-02-11 |
| Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects (NCT02765724) | CTI BioPharma | 2015-01-01 |
| Quantitative MRI for Myelofibrosis (NCT01973881) | University of Michigan Rogel Cancer Center | 2014-12-22 |
| Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies (NCT02129582) | Case Comprehensive Cancer Center | 2014-11-05 |
| PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects (NCT02807077) | CTI BioPharma | 2014-11-01 |